Invus Global Management, LLC - Significant Ownership

Signature - Title
/s/ Raymond Debbane - Raymond Debbane, President
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Invus Global Management, LLC.

Email me when Invus Global Management, LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Invus Global Management, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SRRK Scholar Rock Holding Corporation Common Stock, par value $0.001 per share 11.4% $293M 10.8M Invus Public Equities, L.P. Dec 31, 2024
IVA Inventiva S.A. Ordinary shares, nominal value Euro 0.01 per share 10.6% $52M $26M 14.8M +100% Invus Public Equities, L.P. Jun 30, 2025
RANI Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value 9.99% $4.91M 9.83M Raymond Debbane Oct 16, 2025
BCAX Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share 9.6% $68M 5.22M Raymond Debbane Jun 30, 2025
SLDB Solid Biosciences Inc. Common Stock, $0.001 par value per share 9.6% $20M $9.9M 7.42M +97.8% Raymond Debbane Mar 31, 2025
VTVT vTv Therapeutics Inc. Class A Common Stock, $0.01 par value per share 9.4% $9.18M $1.05M 393K +12.9% Raymond Debbane Sep 30, 2025
TENX Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share 9.4% $2.56M 427K Raymond Debbane Sep 26, 2025
NBTX Nanobiotix S.A. Ordinary shares, nominal value Euro 0.03 per share 8.9% $13.3M 4.23M Invus Public Equities, L.P. Dec 31, 2023
ABVX Abivax S.A. Ordinary shares, nominal value Euro 0.01 per share 8.5% $32.1M 5.4M Invus Public Equities, L.P. Sep 2, 2022
DBVT DBV Technologies S.A. Ordinary Shares, nominal value Euro 0.10 per share 7.8% $115M 11.5M Raymond Debbane Oct 6, 2025
RZLT Rezolute, Inc. Common Stock, $0.001 par value per share 5.4% $34.1M 4.87M Raymond Debbane Sep 18, 2025
TNGX Tango Therapeutics, Inc. Common Stock, $0.001 par value per share 5.3% $40.6M 5.88M Raymond Debbane Sep 19, 2025
VIGL Vigil Neuroscience, Inc. Common Stock, par value $0.0001 per share 4.9% $2.97M 1.99M Raymond Debbane Dec 31, 2024
SYRS Syros Pharmaceuticals, Inc. Common Stock, $0.001 par value per share 3.8% $777K 1.06M Invus Public Equities, L.P. Dec 31, 2024
GOSS Gossamer Bio, Inc. Common Stock, par value $0.0001 per share 2.8% $4.88M 6.26M Invus Public Equities, L.P. Dec 31, 2024
KLRS Kalaris Therapeutics, Inc. Common Stock, $0.0001 par value per share 1.5% $955K 283K Invus Public Equities, L.P. Jun 30, 2025

Schedules 13D/G Reported by Invus Global Management, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.